SCHEMBL6529455

SCHEMBL6529455

COC(=O)[C@@H](CC(C)C)Nc1nc(NCCN(C)C)nc(Nc2cccc(F)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.44
CDK19 Q9BWU1 1/20 0.44
IDH2 P48735 1/20 0.41
NPR3 P17342 5/20 0.40
NPC1 O15118 1/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
SYK P43405 1/20 0.39
CCNT1 O60563 2/20 0.38
CDK2 P24941 2/20 0.38
CDK9 P50750 2/20 0.38
CCNA2 P20248 1/20 0.38
CCNE1 P24864 1/20 0.38
SCN9A Q15858 1/20 0.38
SOS1 Q07889 1/20 0.38
KCNH3 Q9ULD8 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6529452 1.00 CDC7 (0.44) CDC7CDK19IDH2NPR3NPC1
SCHEMBL6529995 0.86 MEN1 (0.52) NPR3NPC1CDK5CDK5R1CYP2C9
SCHEMBL6529989 0.86 MEN1 (0.52) NPR3NPC1CDK5CDK5R1CYP2C9
SCHEMBL6530469 0.85 NPR3 (0.55) NPR3CYP2C9CYP2C19KCNH3CYP1A2
SCHEMBL6530463 0.85 NPR3 (0.55) NPR3CYP2C9CYP2C19KCNH3CYP1A2
SCHEMBL6530426 0.84 ALDH1A1 (0.47) CYP2C9CYP2C19KCNH3CYP1A2
SCHEMBL6530423 0.84 ALDH1A1 (0.47) CYP2C9CYP2C19KCNH3CYP1A2
SCHEMBL6527960 0.83 NPR3 (0.43) IDH2NPR3NPC1CDK5CDK5R1
SCHEMBL6527972 0.83 NPR3 (0.43) IDH2NPR3NPC1CDK5CDK5R1
SCHEMBL6529544 0.82 NPR3 (0.41) CDC7IDH2NPR3CDK5CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO disclosed